glp-1 obesity drugs updates today Market Size to Hit USD 132.79 Bn by 2035 GLP-1s for Weight Loss: What

Cholesterol, glucose and insulin levels, liver fat, and blood pressure all appear to improve with these medications

Int J Mol Sci 2022, 23(23)

Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults

[DOI] [PubMed] [Google Scholar] 38.Gorgojo-Martinez J.J., Mezquita-Raya P., Carretero-Gomez J., Castro A., Cebrian-Cuenca A., de Torres-Sanchez A., Garcia-de-Lucas M.D., Nunez J., Obaya J.C., Soler M.J., et al

Bode BW, Testa MA, Magwire M, et al

Lancet 402(10397):20334 Folkhlsomyndigheten (2023) Statistik om vervikt och fetma hos vuxna